company background image
CVAC logo

CureVac NasdaqGM:CVAC Stock Report

Last Price

US$2.91

Market Cap

US$652.8m

7D

-3.6%

1Y

-50.9%

Updated

13 Oct, 2024

Data

Company Financials +

CVAC Stock Overview

A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

CVAC fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CureVac N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CureVac
Historical stock prices
Current Share PriceUS$2.91
52 Week HighUS$6.30
52 Week LowUS$2.22
Beta2.61
11 Month Change-15.41%
3 Month Change-19.17%
1 Year Change-50.93%
33 Year Change-92.69%
5 Year Changen/a
Change since IPO-94.79%

Recent News & Updates

CureVac: Back To Square One

Oct 08

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Recent updates

CureVac: Back To Square One

Oct 08

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02
CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

Shareholder Returns

CVACUS BiotechsUS Market
7D-3.6%1.2%1.0%
1Y-50.9%21.2%33.7%

Return vs Industry: CVAC underperformed the US Biotechs industry which returned 21.2% over the past year.

Return vs Market: CVAC underperformed the US Market which returned 33.7% over the past year.

Price Volatility

Is CVAC's price volatile compared to industry and market?
CVAC volatility
CVAC Average Weekly Movement8.2%
Biotechs Industry Average Movement9.7%
Market Average Movement6.3%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CVAC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CVAC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,086Alexander Zehnderwww.curevac.com

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.

CureVac N.V. Fundamentals Summary

How do CureVac's earnings and revenue compare to its market cap?
CVAC fundamental statistics
Market capUS$652.75m
Earnings (TTM)-US$304.46m
Revenue (TTM)US$72.02m

9.1x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CVAC income statement (TTM)
Revenue€65.86m
Cost of Revenue€152.13m
Gross Profit-€86.27m
Other Expenses€192.16m
Earnings-€278.43m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.24
Gross Margin-131.00%
Net Profit Margin-422.77%
Debt/Equity Ratio0%

How did CVAC perform over the long term?

See historical performance and comparison